Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 3.70
Change: 0.00 (0.00%)
Spread: 0.68 (22.517%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Loan Agreement

24 Jun 2008 07:05

Proteome Sciences plc ("The Company")

Cobham, England (June 24, 2008) - The Directors of Proteome Sciences plc are pleased to announce that following the release of the preliminary announcement of the results for the year to the 31st December, 2007, the Company has entered into a further loan agreement with C.D.J. Pearce, the Chief Executive of the Company, under which the amount of the facility available has been increased to up to ‚£8m. The agreement is on the same terms as the loan agreement dated 21st February, 2008 save that security for the total loan facility includes a floating charge over the company's stock-in-trade.

In relation to the increase in the loan facility from C.D.J. Pearce, the Directors of the Company, (with the exception of C.D.J. Pearce who, in view of his interest in the transaction, has taken no part in the consideration thereof), having consulted with its nominated adviser, consider that the terms of this transaction are fair and reasonable insofar as shareholders are concerned.

The Report and Accounts for 2007 will be posted to shareholders on the 27th June and the Annual General Meeting will be held on Monday 28th July, 2008.

Ends

About Proteome Sciences:

Proteome Sciences plc is a global leader in applied proteomics, using high sensitivity proprietary techniques to detect and characterise differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications.

ProteoSHOP‚® provides integrated proteomic services for biomarker discovery, validation and measurement in clinical trials and in vitro diagnostics. Key features include the proprietary isobaric tandem mass tag technology TMT‚® for accurate and reliable biomarker quantification and the ability to rapidly develop highly reproducible quantitative biomarker assays.

The main focus of its research addresses neurological, oncology and cardiovascular conditions and has discovered blood biomarkers in stroke, brain damage, solid organ transplant rejection and Alzheimer's disease. Proteome Sciences is based in Cobham, UK with facilities in London and Frankfurt.

Contact Proteome Sciences plc at www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director

Tel: +44 (0)1932 865065

Adrian Shaw, IKON Associates

Tel: +44 (0)1483 535102 / +44 (0)797 9900733

Matt Baldwin, COAST Communications

Tel: +44 (0)1233 503200

Landsbanki Securities (UK) Limited

Shaun DobsonClaes SpĴngTel: +44 (0) 207 426 9000

vendor
Date   Source Headline
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.